Workflow
伟思医疗(688580) - 2021 Q1 - 季度财报
VISHEEVISHEE(SH:688580)2021-04-27 16:00

Financial Performance - Operating revenue for the period was ¥80,199,797.02, representing a year-on-year increase of 40.66%[5] - Net profit attributable to shareholders was ¥31,281,901.82, an increase of 84.17% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥25,912,028.42, up 72.51% year-on-year[5] - Basic earnings per share increased to ¥0.4577, a rise of 38.11% compared to the previous year[5] - The company reported a total comprehensive income for Q1 2021 of ¥31,281,901.82, compared to ¥16,985,782.80 in Q1 2020, indicating an 84.5% increase[25] - The total profit for Q1 2021 was ¥35,400,822.19, compared to ¥19,275,946.26 in Q1 2020, marking an 83.9% increase[24] - Net profit for Q1 2021 was ¥31,143,408.53, up 83.8% compared to ¥16,941,112.78 in Q1 2020[24] Cash Flow - The cash flow from operating activities was ¥6,173,884.92, a significant recovery from a negative cash flow of ¥30,313,831.85 in the same period last year[5] - The net cash flow from operating activities was ¥11,389,801.86 in Q1 2021, recovering from a net outflow of ¥22,227,738.05 in Q1 2020[31] - The total cash outflow from operating activities was ¥77,164,643.53 in Q1 2021, up from ¥69,187,602.38 in Q1 2020[31] - The company reported a net increase in cash and cash equivalents of -¥369,062,716.93 in Q1 2021, compared to -¥30,757,465.17 in Q1 2020[32] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,548,283,276.52, an increase of 0.51% compared to the end of the previous year[5] - Total current assets amounted to RMB 1.42 billion, slightly up from RMB 1.42 billion at the end of 2020[17] - Current liabilities decreased to CNY 106,483,189.84 from CNY 128,677,351.40, reflecting a reduction of approximately 17.3%[18] - Total liabilities decreased to CNY 110,724,451.31 from CNY 129,453,569.35, a decrease of approximately 14.5%[19] - The company’s minority interests decreased by 60.69% to RMB 1.96 million due to the acquisition of partial equity in a subsidiary[14] - Total non-current liabilities reached 776,217.95, with no significant adjustments noted[42] Research and Development - R&D investment accounted for 12.84% of operating revenue, an increase of 1.24 percentage points compared to the previous year[7] - Research and development expenses increased by 55.69% to RMB 10.30 million, reflecting higher employee compensation[14] - Research and development expenses increased to ¥10,297,726.89, representing a 55.5% rise from ¥6,614,086.04 in Q1 2020[23] Shareholder Information - The total number of shareholders at the end of the reporting period was 6,275[9] - The top shareholder, Wang Zhiyu, holds 39.45% of the shares, totaling 26,961,547 shares[9] Investment Activities - Investment income surged by 207.02% to RMB 3.52 million, driven by increased investment in financial products[14] - Total cash inflow from investment activities was ¥688,409,472.62 in Q1 2021, significantly up from ¥227,374,566.19 in Q1 2020, marking a 202.5% increase[32] - The cash outflow for investment activities totaled ¥1,068,596,178.21 in Q1 2021, compared to ¥230,738,995.59 in Q1 2020, resulting in a net cash flow of -¥380,186,705.59[32] Other Financial Metrics - The weighted average return on net assets decreased by 4.39 percentage points to 2.20%[5] - The company achieved operating revenue of RMB 80.20 million in Q1 2021, representing a growth of 40.66% compared to the same period last year[12] - Total operating costs for Q1 2021 were ¥53,670,086.70, a 30.2% increase from ¥41,200,565.97 in Q1 2020[23] - The company reported an operating profit of ¥33,216,672.19 for Q1 2021, up 75.5% from ¥18,935,198.80 in Q1 2020[24]